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ABSTRACT
The CXXC5 gene encodes a transcriptional activator with a zinc-finger domain, 
and high expression in human acute myeloid leukemia (AML) cells is associated with 
adverse prognosis. We now characterized the biological context of CXXC5 expression 
in primary human AML cells. The global gene expression profile of AML cells derived 
from 48 consecutive patients was analyzed; cells with high and low CXXC5 expression 
then showed major differences with regard to extracellular communication and 
intracellular signaling. We observed significant differences in the phosphorylation 
status of several intracellular signaling mediators (CREB, PDK1, SRC, STAT1, p38, 
STAT3, rpS6) that are important for PI3K-Akt-mTOR signaling and/or transcriptional 
regulation. High CXXC5 expression was also associated with high mRNA expression 
of several stem cell-associated transcriptional regulators, the strongest associations 
being with WT1, GATA2, RUNX1, LYL1, DNMT3, SPI1, and MYB. Finally, CXXC5 
knockdown in human AML cell lines caused significantly increased expression of 
the potential tumor suppressor gene TSC22 and genes encoding the growth factor 
receptor KIT, the cytokine Angiopoietin 1 and the selenium-containing glycoprotein 
Selenoprotein P. Thus, high CXXC5 expression seems to affect several steps in human 
leukemogenesis, including intracellular events as well as extracellular communication. 
INTRODUCTION
CXXC5 is a retinoid-responsive gene localized 
to the 5q31.3 chromosomal region [1] and encoding a 
retinoid-inducible nuclear factor (RINF) [2] that is a 
protein containing a CXXC-type zinc-finger domain 
and acting as a transcription regulator [3]. Expression 
studies as well as gene silencing experiments suggest 
that CXXC5 is important in normal myelopoiesis [2] and 
for differentiation of endothelial cells [3]. Furthermore, 
we recently described that CXXC5 is expressed in 
primary acute myeloid leukemia (AML) cells; this 
expression shows a wide variation between patients and 
high levels are associated with an adverse prognosis 
and resistance to chemotherapy-induced apoptosis [4]. 
Another study recently confirmed our observations and 
CXXC5 expression was then of independent prognostic 
significance in multivariate analyses after adjustment 
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for age, white blood cell count, cytogenetic risk group, 
FLT3-ITD status, biallelic CEBPA mutations, as well as 
mutations of NPM1, DNMT3A and ASXL1 [5]. Based on 
these observations we suggest that CXXC5 should be 
considered as a possible therapeutic target in human AML. 
However, more detailed preclinical evaluation of CXXC5 
as a possible therapeutic target is needed. In the present 
study we characterized the biological context of high 
CXXC5 expression and effects of CXXC5 knockdown in 
human AML cells. 
MATERIAL AND METHODS
AML patients and preparation of primary AML 
cells
The study was approved by the Regional Ethics 
Committee III, University of Bergen, Norway). Samples 
were collected after written informed consent, and we 
included consecutive and thereby unselected patients with 
high peripheral blood blast counts (>7 x 109/L) (Table 1). 
These selections of patients as well as the analysis of FLT3 
and NPM1 mutations have been described previously [6, 
7]. AML cells were isolated by density gradient separation 
alone (Lymphoprep, Axis-Shield, Oslo, Norway) and 
contained at least 95% leukemic blasts. The cells were 
stored in liquid nitrogen until used in the experiments 
[6]. CXXC5 expression was determined by PCR analysis 
for a cohort of 67 consecutive patients and global gene 
expression profiles were analysed in a second cohort of 48 
consecutive patients; there was an overlap of 24 patients 
between the cohorts (see later, Suppl. Fig. 1). 
AML cell lines
Human leukemic cell lines were purchased from 
DSMZ (MV4-11; Braunschweig, Germany) and from 
the American Type Culture Collection (K562; Molsheim, 
France). UT7 5.3 cells were kindly provided by Isabelle 
Dusanter-Fourt (Cochin Institute, Paris, France). K562 
and MV4-11 were cultured in RPMI 1640 medium 
supplemented with 10% fetal calf serum (FCS), 2 
mM L-Glutamine, 50 U/ml penicillin G and 50 µg/ml 
streptomycin (Life Technologies, Saint-Aubin, France). 
UT7 5.3 cells were cultured in minimum essential 
medium (MEM) α medium containing 10% of FCS, 2 
mM L-Glutamine, 50 U/ml penicillin G and 50 µg/ml 
streptomycin (Life Technologies, Saint-Aubin, France) 
and 2,5 ng/µl of GM-CSF (Myltenyi Biotech, France).
RNA purification and quantitative RT-PCR 
analysis of CXXC5 messenger RNA expression 
The methods for purification of total RNA, 
complementary DNA synthesis and quantitative PCRs 
(qPCR) have been described in detail previously [4]. 
Relative messenger RNA (mRNA) expression was 
normalized to ribosomal protein P2 (RPLP2) gene 
expression in a two-colour duplex reaction.
RNA preparation, labeling and microarray 
hybridization for primary human AML cells
 Microarray analyses were performed using Illumina 
iScan Reader based on fluorescent detection of biotin-
labeled cRNA. Total RNA (300 ng) from each sample 
was reversely transcribed, amplified and Biotin-16-UTP-
labelled using Illumina TotalPrep RNA Amplification 
Kit (Life Technologies, Foster City, CA, USA). Amount 
and quality of biotin-labeled cRNA was controlled by 
NanoDrop spectrophotometer and by Agilent 2100 
Bioanalyser (Agilent Technologies, Santa Clara, CA, 
USA). Biotin-labeled cRNA (750 ng) was hybridized 
to HumanHT-12V4 Expression BeadChip according to 
the manufacturer’s instructions. The HumanHT-12V4 
BeadChip targets 47231 probe was based primarily 
on genes in the National Center for Biotechnology 
Information RefSeq database (Release 38; ftp://ftp.cbi.
edu.cn/pub/database/refseq/release/release-notes/archive/
RefSeq-release38.txt).
In vitro culture of primary human AML cells
Drugs. Lenalidomide (Selleck Chemicals, Munich, 
Germany) was used at 0.5 µM. The mTOR inhibitor 
rapamycin was purchased from LC Laboratories (Woburn, 
MA, USA) and the pan-PI3K inhibitor GDC-0941 from 
Axon Mechen (BV, Groningen, the Netherlands); both 
were used at 1.0 µM. 17-dimethylaminoethylamino-
17-demethoxygeldanamycin (17-DMAG) (Infinity 
Pharmaceuticals, Cambridge, MA, USA) was used at 
1.0 µM. Bortezomib was purchased from Jansen-Cilag 
(Beerse, Belgium) and used at 25 nM. Ingenol-3 angelate 
(PEP005) was supplied by Peplin Ltd (Brisbane, Australia) 
and used at 20 nM. Protein kinase inhibitors were all 
purchased from Biaffin GmbH (Kassel, Germany); 
PD98059 was used at 20 μM whereas SB202190 and 
SP600125 were used at 1 μM. All drug solutions except 
GDC-0941 were prepared in dimethylsulphoxide (DMSO) 
or ethanol; pilot experiments demonstrated that DMSO or 
ethanol at the final concentrations used in the experiments 
did not affect AML cells. 
Cell culture. Cells were cultured in StemSpan 
serum-free medium supplemented with 100 µg/ml of 
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gentamicin (Stem Cell Technologies Inc, Vancouver, 
BC, Canada) [8]. AML cells (1 x 106 cells/ml) were 
cultured at 37ºC in a humidified atmosphere of 5% CO2. 
Cytokine levels in supernatants were analysed by Luminex 
methodology after 48 hours of culture (Bio-Plex human 
cytokine group, Bio-Rad, Oslo, Norway) [7-9]. AML cell 
viability/apoptosis was analysed by flow cytometry [10, 
11].
Intracellular protein phosphorylation 
Protein phosphorylation was analyzed by flow 
cytometry as described in detail previously [12-14].
CXXC5 knockdown and global gene expression 
analyses of AML cell lines
CXXC5 knockdown. K562 and UT7.3 cells were 
transduced with the pTRIP lentiviral vector that drives 
the constitutive expression of GFP (Green Fluorescent 
Protein) for cell sorting, and either a short-hairpin RNA 
[shRNA] targeting RINF sequence (shRNA-RINF) or 
a non-relevant sequence (non-target-shRNA control) 
as described in detail previously [1]. K562 and MV4-
11 were also transduced with the previously described 
pLKO.1/shRNA-RINF and pLKO.1/shRNA-nontarget 
that drives the expression the puromycine resistant gene 
for the selection of the cells [1]. Lentiviral plasmids 
(pLKO.1/short hairpin RNA [shRNA]/RINF) targeting 
RINF expression were purchased from Sigma-Aldrich 
(MISSION shRNA Bacterial Glycerol Stock), and control 
vectors (pLKO.1/TRC and pLKO.1/shRNA/scramble 
controls) were kindly provided by David Root and 
David M. Sabatini (both from Massachusetts Institute of 
Technology, Cambridge, MA; Addgene plasmids 10879 
and 1864). Briefly, production of lentiviral particles were 
performed by transient cotransfection (with Fugene HD) 
of HEK 293T cells with the second generation packaging 
system (e.g., packaging plasmid psPAX2 and envelope 
plasmid pMD2.G) developed by D. Trono’s laboratory 
(Ecole Polytechnique Fédérale de Lausanne, Lausanne, 
Switzerland; Addgene plasmids 12260 and 12259). 
Viral supernatants were harvested and filtered 2 days 
posttransfection and then applied to growing cells for 
spin infection (2400 rpm for 1 hour at room temperature), 
which was carried out in presence of 5 μg/mL proteamine 
sulfate. Two days after infection, AML cells were selected 
for at least 2 days with puromycine (Sigma-Aldrich) at 1 
μg/mL.
Our methods for knockdown, verification of the 
knockdown at the protein and mRNA level, and analysis 
of the effects of knockdown on proliferation and apoptosis 
have been described in detail in our previous publication 
[4]. The knockdown alone did not affect proliferation or 
viability of the AML cell lines, and the efficiency of the 
knockdown was verified both at the mRNA and protein 
level for each cell line in every experiment. 
Analysis of global gene expression profiles. 
After validation of RNA quality with Bioanalyzer 2100 
(using Agilent RNA6000 nano chip kit), 400 ng of total 
RNA was reverse transcribed  following the Genechip 
WT plus Reagent kit (Affymetrix). Briefly, the resulting 
double strand cDNA was used for in vitro transcription 
with T7 RNA pol. After purification, 15 µg of cRNA was 
used for reverse transcription with random primers. The 
cDNA obtained was then purified and fragmented. After 
control of fragmentation using Bioanalyzer 2100, cDNA 
was end labeled with biotin using Terminal Transferase 
(using the WT terminal labeling kit of Affymetrix). cDNA 
was then hybridized to GeneChip® Human Transcriptome 
Analysis 2.0 (Affymetrix) at 45°C for 17 hours. After 
overnight hybridization, chips were washed on the fluidic 
station FS450 following specific protocols (Affymetrix) 
and scanned using the GCS3000 7G. The image was then 
analyzed with Expression Console software (Affymetrix) 
to obtain raw data (cel files) and metrics for Quality 
Controls. Minimum information about a microarray 
experiment (MIAME)–compliant documentation of the 
microarray experiments have been deposited in Array 
Express at the European Bioinformatics Institute (http://
www.ebi.ac.uk/arrayexpress). The Affymetrix HTA2 
dataset analysis was performed by GenoSplice technology 
(www.genosplice.com). Data were normalized using 
quantile normalization. Background corrections were 
made with antigenomic probes and probes were selected 
according to their %GC, cross-hybridization status 
and potential overlap with repeat region as previously 
described [15, 16]. Only probes targeting exons and exon-
exon junctions annotated from FAST DB® transcripts 
(release fastdb_2014_1) were selected [17, 18]. Only 
genes expressed in at least one compared condition were 
analyzed. To be considered to be expressed, the DABG 
P-value had to be ≤0.05 for at least half of the gene probes. 
We performed an unpaired Student’s t-test to compare 
gene intensities between shRINF and shCTRL cells. 
Genes were considered significantly regulated when fold-
change was ≥1.5, a fold-change noticed for CXXC5 genes 
for which we have validated the knock-down by q-RT-
PCR and western-blot analysis. 
Analyses of the data 
For statistical comparisons between different groups 
we used the Mann-Whitney U-test, for analyses of paired 
observations the Wilcoxon’s signed rank test was used and 
for correlation analyses we used the Pearson’s correlation 
test. Differences were regarded as significant when p<0.05. 
Bioinformatical analyses of gene expression data were 
performed using the J-Express (MolMine AS, Bergen, 
Norway); whereas our analysis of protein functions was 
based on the Panther (http://www.pantherdb.org/) and 
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Reactome (http://www.reactome.org/) databases. 
RESULTS
Global gene expression profiles differ between 
AML cells with high and low CXXC5 expression
CXXC5 expression was analyzed by PCR for 
a total of 67 patients who were included in the study 
(Table 1). When comparing the 34 patients with low 
and the 33 patients with high CXXC5 expression we 
confirmed that monocytic differentiation of the leukemic 
cells (FAB-M4/M5) was associated with low expression 
compared with neutrophilic differentiation (FAB-M2) 
[4], whereas CXXC5HIGH and CXXC5LOW patients did 
not differ significantly for any other parameter, including 
the percentage of patients with at least one risk factor 
for chemoresistance (i.e. secondary leukemia, relapsed 
disease, adverse cytogenetic abnormalities or Flt3-
ITD). Similar results were observed when comparing 
CXXC5HIGH and CXXC5LOW patients in the microarray 
cohort (n=48) (data not shown). Both cohorts included 
consecutive and thereby unselected patients and 24 
patients were included in both cohorts; a strong correlation 
was then observed for these patients when comparing 
CXXC5 levels determined by PCR and microarray 
analyses (Suppl. Fig. 1; r=0.7665 p<0.0001, Pearson’s 
correlation test). 
We did a Gene Set Enrichment Analysis (GSEA) 
where we compared the 15 patients with the highest and 
the 15 patients with the lowest CXXC5 expression, and 
we then identified 38 GO-terms with a false discovery 
rate (RDR) <1.0. All GO-terms were enriched in the 
CXXC5LOW group, and we identified 571 genes that 
belonged to the leading edge for at least one of these 38 
terms. When these 571 genes were used in a hierarchical 
clustering analysis we identified two main subsets 
corresponding to the original CXXC5LOW and CXXC5HIGH 
patient subsets (Suppl. Fig. 2). 
The 38 GO-annotations identified above (Suppl. Fig. 
2) could be classified into three main groups; extracellular 
communication (9 annotations), intracellular signaling and 
trafficking (13 annotations), and a third heterogeneous 
group including regulation of cell shape, inflammatory 
and metabolic responses (16 annotations) (Supplementary 
Table 2). Firstly, CXXC5HIGH and CXXC5LOW patients 
differed with regard to extracellular communication 
including cytokine production (IL6, TNFα), integrin-
mediated signaling and expression of immunoglobulin 
superfamily members (i.e. a family including adhesion 
molecules and cytokine receptors). Secondly, the 
intracellular signaling and trafficking group included 
the wide terms Response to zinc and Lysosome, but in 
addition terms reflecting differences in signaling mediated 
by Toll-like receptor-linked pathways, MAP kinases and 
ARF/GTP-ase. The differences in intracellular trafficking 
Figure 1: Protein class analysis of the genes showing differential expression for CXXC5HIGH and CXXC5LOW patients 
in GSEA analysis (left, 571 genes identified) and similarity profiling analysis (right, the 200 genes with the strongest 
correlation being analyzed). The genes were analyzed according to their functional protein class based on the Panther (http://www.
pantherdb.org/) database. The various protein classes were ranked according to the number genes included in each of the classes. 
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Table 1: Clinical and biological characteristics of the AML patients included in the study.
Parameter All 67 patients Low CXXC5 expression34 patients
High CXXC5 
expression
33 patients
Age (years; median/range) 64 years (27-88 years) 61 years (29-88 years) 70 years (27-83 years)
Gender distribution (female/male) 30/37 16/18 13/20
Percentage of patients with:
AML secondary to chemotherapy
AML secondary to myeloid malignancies (MDS, 
chronic myeloid neoplasia)
de novo AML 
8%
24%
68%
12%
18%
70%
3%
30%
67%
Relapse at the time of examination 21% 15% 27%
FAB classification
M0/M1
M2
M4/M5
36%
26%
38%
24%
27%
49%
48%
26%
26%
Expression of CD34 (>20% positive AML cells) 54% 54% 54%
Cytogenetic abnormalities
Normal
Good
Intermediate
Adverse
59%
8%
9%
27%
54%
17%
4%
25%
64%
0
12%
30%
Flt3 internal tandem duplication (ITD) 32% 29% 37%
NPM-1 mutations 45% 45% 45%
Favourable cytogenetic abnormalities include inv(16)/t(16;16) and t(8;21); adverse include multiple (≥ 3 abnormalities), 
t(3:3), del7 and del5.
Figure 2: CXXC5/RINF expression is correlated with the expression of several transcriptional regulators in primary 
human AML cells. Global gene expression analyses were performed for 48 consecutive/unselected AML patients, and we then compared 
expression of CXXC5 with the expression of WT1, GATA2, MLL, RUNX1, LYL1 and DNMT3B. 
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Table 2: Comparison of AML cells showing high and low CXXC5 expression - identification and classification 
of important proteins encoded by the 571 genes identified from the leading edge in the Gene Set Enrichment 
Analysis (Supplementary Figure 2). The PANTHER protein classification (Figure 1) identified 4 major classes of 
proteins, the table describes the most important subclasses within the 4 main protein classes. The main classes are 
numbered according to the classification in Figure 1. 
CLASS 1. RECEPTOR (total protein class hits 68)
1a G-protein coupled receptor (24/68 genes)
The largest subset was chemokine receptors (CCR1/2/7, CXCR1/4, CX3CR1); three adenosine receptors 
(ADORA3, ADORA2, AADORA2B)
1b Cytokine receptor (36/68 genes)
LILR and CLEC receptors were also included in this term (see 18b below).
Interleukin receptors: IL4R, IL8R1, IL10RB, IL18RAP, IL27β
Others: FAS, TNFRSF1B
CLASS 2. HYDROLASES (total protein class hits 53)
2a. Phosphatase (9/53 genes)
Including the INPPL1 (phosphatidylinositol 3,4,5-triphosphate 5 phosphatase 2) together with A base subunits 
(ATP6V0E172), one receptor-type (PTPRJ) and one no receptor (PTPN6)  tyrosine-protein phosphatase. 
2b Proteases (35/53 genes)
The complement system: C2, CD45, CFB, CFD, CF1, CR1,
Cathepsins: CTSA, CTSB, CTSD, CTSG, CTSK, CTSL1, CTSL2, CTSS, CTSZ
Others: Caspase 1, Matrix metalloprotease 9 and 25.
CLASS 3. DEFENSE/IMMUNITY PROTEINS (total protein class hits 53) 
3a Immunoglobulin receptor superfamily (25/53 genes)
HLA molecules: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F
C-type lectin receptors (CLEC1A, CLEC5A, CLEC7A), Leukocyte Immunoglobulin Like Receptors 
(LILRA1-3, LILRB2/3/5).
Others: CD1D, CD4, Face-receptors (FCGR1A, FCGR1B 
CLASS 4. SIGNALING MOLECULE (Total protein class hits 48)
18a Cytokine (23/48 genes), the main subsets being:
Chemokines: CCL2/3/5/16/20/23, CXCL16
Receptor for G-CSF
The Interferon system: IFNA4, IFNA16, IFNB1
The Interleukin system: (i) IL6 and its downstream targets IL6ST and SOCS3; IL1RA, IL17F, IL27RA
Lymphotoxin A and TNF
18b Membrane-bound signaling molecules (17/48 genes), including: 
NOTCH2 
(LILR and CLEC, see 1b above)
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involved endocytic uptake. Finally, the third group 
included responses to pH as well as responses to infections 
(related to Toll like receptor signaling), regulation of 
inflammation, and regulation of cell shape.
We did an alternative bioinformatical analysis of 
the 571 genes identified above (Supplementary Figure 
2); we then used the Panther database and the genes were 
analyzed with regard to classification of the encoded 
proteins (Figure 1 left; total protein class hits 800). The 
four main classes had the following characteristics (Table 
2):
Defense/immunity proteins. The majority of 
genes with different expression were C-type lectin-like 
receptors (CLEC), HLA molecules (especially class I 
molecules), and leukocyte immunoglobulin-like receptors 
(LILR). CLECs and HLA-class I molecules seem to 
have functional interactions [19] and HLA-molecules are 
ligands for LILR [20].
Hydrolases. The different expression of 
phosphatidylinositol 3,4,5-triphosphate 5 phosphatase 
2 was the only phosphatase suggesting a difference in 
specific signaling pathways. The most important subset 
in this class was the hydrolases; differential expression 
was then seen for several genes encoding members of 
the complement system, cathepsins that are important 
for lysosomal functions [21, 22], and the Matrix 
Metalloprotease 9 that causes proteolytic cleavage of 
chemokines (e.g. CXCL8, CXCL12) and thereby may be 
involved in leukemogenesis [23].
Receptors. The functions of several cytokine 
receptors differed, including both the chemokine and the 
interleukin system as wells as Fas and the G-CSF and 
TNF receptors. We also observed altered expression of 
adenosine receptors that may have a role in regulation of 
apoptosis in human AML [24, 25].
Signaling molecules. The expression of cytokines is 
also altered, including members of both the chemokine, 
interferon and interleukin systems (especially IL6 
signaling). 
Thus, the major differences between CXXC5HIGH 
and CXXC5LOW AML include the following functional 
networks (Table 2): (i) HLA-class I-CLEC-LILR; (i) 
the chemokine-chemokine receptor system (including 
MMP9); (iii) the interleukin system; (iv) the complement 
system; and (v) the lysosomal function and thereby 
possibly also regulation of autophagy and cell viability 
[21, 22].
CXXC5 expression is correlated with the 
expression of several hematopoietic transcription 
factors that are associated with adverse prognosis
Similarity profiling was used to further analyze the 
global gene expression data and we identified the 200 
genes whose expression showed the strongest correlation 
with CXXC5 expression; those genes with a known 
function according to the PubMed and Gene databases are 
listed in Supplementary Table 2. A large subset of these 
genes is important for gene transcription, the largest group 
being zinc finger proteins and their interacting proteins. 
Another large subset was genes important for intracellular 
signaling including cell surface molecules as well as 
intracellular mediators. Alternatively, we also investigated 
the functional importance of the proteins encoded by 
the 200 genes showing the strongest correlation with 
CXXC5 expression in the similarity profiling analysis. 
When this analysis was based on the Panther database we 
confirmed that a majority of the genes encodes proteins 
that are important for transcriptional regulation (Figure 
1, right). The importance of transcriptional regulation 
was further confirmed by an alternative analysis based 
on the Reactome database, and this last analysis in 
addition suggested that the function of SMAD3 and 
SMAD4 is altered. The SMAD-signaling pathway 
operates downstream of the transforming growth factor-β 
(TGF-β) superfamily of ligands; it seems to be important 
for regulation of normal and possibly also leukemic 
hematopoietic stem cell functions including regulation 
of proliferation, differentiation and apoptosis [26-32]. 
Finally, some of the terms from the Gene Set Enrichment 
Analysis were as expected also detected at a lower 
frequency in the similarity analysis (see Figure 1, right 
part). 
A subset of AML patients with adverse prognosis 
shows high expression of certain hematopoietic stem 
and progenitor cell-associated transcription factors 
[33-35], especially the heptade SCL, LYL1, LMO2, 
GATA2, RUNX1, FLI1 and ERG [34]. With regard to 
this heptade we observed strong correlations between 
CXXC5 expression and expression of the four genes LYL1 
(p<0.0001, r=0.7434), GATA2 (p<0.0001, r=0.6592), 
RUNX1 (p<0.0001, r=0.6372) and ERG (p=0.0212, 
r=0.3318); the correlations did not reach significance 
for the two factors SCL (p=0.1076, r=0.2352) and FLI1 
(p=0.1866, r=0.3760) (Figure 2); and even though CXXC5 
expression did not show any significant correlation 
with the expression of the last factor LMO2 (p=0.4815, 
r=0.1041) it showed a strong correlation with expression 
of LYL1 that is necessary for recruitment of LMO2 to 
DNA [36, 37]. Furthermore, CXXC5 expression also 
showed significant correlations with the expression of 
several other transcriptional regulators, including WT1 
(p<0.0001, r=0.5403), DNMT3B (p<0.0001, r=0.5308), 
MLL (p=0.0029, r=0.4205), SPI1 (p=0.0001, r=0.5222), 
MYB (p=0.0004, r=0.4930) and GFI1B (p=0.0110, 
r=0.3641). 
We finally investigated the association between 
CXXC5 expression and the overall expression profile 
of the transcription factor heptade. We then analyzed 
the expression of all 7 transcription factors for the 15 
AML patients with the highest and the 15 patients with 
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the lowest CXXC5 expression (Figure 3), and we did 
a clustering analysis of these 30 patients based on the 
expression profile of the 7 factors. The overall heptade 
signature separated the patients into two main subsets 
corresponding to the CXXC5HIGH and CXXC5LOW subsets. 
Thus, clustering analysis shows that CXXC5/RINF 
expression shows a strong correlation with several other 
transcription factors involved in hematopoiesis, including 
several members of the transcription factor heptade 
(GATA2, RUNX, ERG, the LM02 recruitment factor 
LYL1) that is associated with adverse prognosis in AML 
[35]. 
High CXXC5 mRNA expression is associated 
with a stem cell signature that has an adverse 
prognostic impact 
Eppert et al. [33] identified gene expression 
signatures for normal hematopoietic and AML stem cells, 
and three gene subsets were then identified: (i) genes 
showing differential expression in leukemic stem cells 
(LSC-related); (ii) genes showing differential expression 
in normal hematopoietic progenitor/stem cell (HSC-
related) with a subset of these genes also being highly 
expressed in AML stem cells; and (iii) a subset of genes 
driving the expression of HSC-related genes in AML stem 
cell. Thereafter they compared the AML cell expression of 
these genes for patients with good and adverse prognosis, 
and based on this comparison they identified 35 genes 
associated with adverse prognosis. Eight of these genes 
were among the 650 highest ranked genes in the similarity 
profile analysis and thus showed very strong correlation 
with CXXC5 expression (GPR56, ANGPT1, SLC9A7, 
GOLGA8, TUG1, LOC552889, PIK3C2B, RABGAP1; 
p<0.0001 for all), and CXXC5 expression showed 
weaker but still significant correlations (p<0.05) with 18 
additional genes (Figure 4). We compared the expression 
of these 35 genes for our 15 patients with the highest and 
the 15 patients with the lowest CXXC5 expression (Figure 
4). Based on this clustering analysis we identified two 
main patient subsets including a majority (13 out of 15) 
CXXC5HIGH and CXXC5LOW patients, respectively. Thus, 
high CXXC5 expression is also associated with this stem 
cell signature that has an adverse prognostic impact. 
CXXC5HIGH and CXXC5LOW AML cells show only 
minor differences in their cytokine secretion
Our GSEA analysis suggested that regulation of 
cytokine release (especially IL6 and TNFα) differed 
between CXXC5HIGH and CXXC5LOW patients, and several 
of the membrane receptors or intracellular pathways 
showing differential expression are also important for 
regulation of cytokine release (see Table 2). For this 
Figure 3: Expression of CXXC5 versus the expression of the transcription factor heptade SCL, LYL1, LMO2, GATA2, 
RUNX1, FLI1 and ERG. The expression of these transcription factors is associated with adverse prognosis [34]. We compared the 
15 patients with the highest and the 15 patients with the lowest CXXC5 expression based on our global gene expression profiling for 48 
unselected AML patients. We did a hierarchical clustering analysis; based on this transcription factor signature the clustering analysis 
identified to major subsets corresponding to the CXXC5HIGH and CXXC5LOW patient subsets. Thus, CXXC5 expression is not only associated 
with the expression of single transcription factors but also with the overall heptade signature.
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reason we compared the constitutive cytokine release for 
the 10 patients in the PCR-analyzed patient cohort with 
the highest and the 10 patients with the lowest CXXC5 
expression in their AML cells. Lenalidomide was also 
investigated because this drug is used in the treatment of 
patients with myelodysplastic syndrome (MDS) and the 
del(5q) abnormality that leads to loss of one CXXC5 gene 
and low CXXC5 expression (1). Firstly, the constitutive 
cytokine release did not differ between CXXC5HIGH and 
CXXC5LOW patients and showed a similar wide variation 
for both groups without any statistically significant 
differences (Supplementary Table 3). Secondly, we also 
did unsupervised hierarchical clustering analyses; the 
two groups then differed in their constitutive cytokine 
release clustering and the most striking difference was 
a very close chemokine clustering (especially CCL2-4 
and IL-8/CXCL8) detected only for CXXC5LOW patients 
(Supplementary Figure 3). The variations between patients 
Figure 4: Expression of CXXC5 versus the expression of a stem cell signature associated with adverse prognosis in 
AML patients receiving intensive chemotherapy [33]. The previous study by Eppert et al identified 35 genes that were expressed 
by leukemic stem cells and associated with an adverse prognosis. We compared the 15 patients with the highest and the 15 patients with 
the lowest CXXC5 expression in our global gene expression profiling for 48 unselected AML patients. We did a hierarchical clustering 
analysis. Based on this analysis of the stem cell signature we identified two main patient subset; one subset included the majority of AML 
patients showing high CXXC5 expression in their leukemic cells (13 out of 15 patients; left main cluster) whereas the other main subset 
included the majority of patients with low CXXC5 expression (also 13 out 15 patients). Thus, CXXC5 expression is not only associated 
with the expression of single stem cell associated genes but also with the overall leukemic stem cell signature. All genes included in this 
analysis (see right part of figure) showed a statistically significant correlation with CXXC5 expression (p<0.05) except for the 9 genes 
GPR21, LOX, MEF2C, NEK9, NIPAL2, PRPF6, RTN2, SLC25A32, TRIP10.
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could not be explained by differences in spontaneous 
apoptosis/viability during culture (data not shown). 
Thirdly, we compared the effect of lenalidomide on the 
release of individual cytokines (Supplementary Table 
4); for the CXXC5LOW group lenalidomide caused a 
significant reduction of IL1β, TNFα and GM-CSF, 
whereas for the CXXC5HIGH group a decrease was seen for 
IL1β, TNFα, IL6 and IL1RA. The percentage reduction 
of the cytokine levels differed significantly between the 
two groups only for IL6 (48.1% reduction for CXXC5HIGH 
versus 78.7% for CXXC5LOW patients, Mann Whitney 
U-test, p=0.0464). Our gene expression studies suggested 
differences in IL6 and TNFα release (Table 2), and this 
was thus supported by our protein studies. However, we 
conclude that the differences in cytokine clustering and 
the lenalidomide-induced alterations should be regarded as 
minor differences in cytokine release; the main difference 
between individual patients being the wide variation in 
cytokine release (more than 104-fold for several cytokines, 
see Supplementary Table 3) that is independent of CXXC5 
expression. 
Figure 5: The intracellular phosphorylation status and phospho-responsiveness of primary human AML cells derived 
from patients with high and low constitutive mRNA CXXC5/RINF expression. A total of 42 patients were included in these 
studies, and the phosphoprotein status was examined by flow cytometry. (A) The basic phosphorylation status was compared for the 
21 patients with the highest and the 21 patients with the lowest CXXC5 expression. The results are presented as the mean and standard 
deviation for the MFI values. Significant differences between the two groups are indicated in the figure (* p<0.05, ** p<0.01). (B) We then 
compared the phosphorylation responsiveness for the 7 patients with lowest CXXC5/RINF expression and the 10 patients with the highest 
CXXC5/RINF mRNA levels. The leukemic cells were cultured with 7 exogenous cytokines (see left margin), and median fold alteration 
(see right margin) for each cytokine/mediator is presented for each of the two groups. (C) The fold change of STAT5 phosphorylation was 
also compared for the 21 CXXC5LOW and CXXC5HIGH patients; these results are presented as the fold change. 
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CXXC5HIGH and CXXC5LOW AML cells differ 
in their intracellular protein phosphorylation 
profile, including phosphorylation of several 
transcriptional regulators 
Our global gene expression studies suggest that 
patients with high and low CXXC5 expression differ in 
their intracellular signaling. We therefore examined the 
phosphorylation status of 19 intracellular mediators in 
primary human AML cells derived from 42 unselected 
patients in our global gene expression patient cohort. 
The intracellular mediators and the exogenous cytokines 
added during incubation were selected based on previous 
observations. Firstly, the intracellular phosphoprotein 
networks investigated (pathways or single mediators 
integrating signaling through several pathways) are 
important for downstream signaling from growth factor 
receptors commonly expressed by primary human AML 
cells [12, 13]. Secondly, ligation of these growth factor 
receptors by exogenous cytokines not only initiates 
alterations in protein phosphorylation but also increases 
[38-40] primary AML cell proliferation and/or modulates 
cytokine-dependent proliferation [41] for a majority of 
patients when tested in standardized in vitro models. 
The patients showed an expected wide variation of 
CXXC5 expression in their AML cells. As explained above 
all the 19 intracellular mediators can be constitutively 
phosphorylated and/or become phosphorylated in 
response to cytokine exposure of primary human AML 
cells, but our high-throughput flow-cytometry technique 
required an incubation prior to analysis in culture medium 
containing insulin and transferrin [12, 13, 42]. This 
medium was used because it is suitable for extended 
in vitro culture of primary human AML cells [43, 44]. 
Our basal phosphorylation status thus refers to the 
phosphoprotein profile under the influence of these two 
mediators but without additional hematopoietic growth 
factors. The comparison of the basal phosphorylation for 
the 21 patients with the highest and the 21 patients with 
the lowest CXXC5 expression showed several differences 
in intracellular signaling and transcriptional regulation 
with increased phosphorylation of CREB (S133), PDK1 
(S241), Src (Y241), STAT3 (Y705), STAT3 (S727), p38 
(Y182) and rpS6 (S235/6) for the CXXC5LOW patients 
(Figure 5A). Several of these mediators are involved in 
PI3K-Akt-mTOR mediated signaling, including PDK1 
[45], Src [46], rpS [47], and the transcription factor CREB 
that is a downstream target of the pathway [48]. STAT3 
can also can be activated by Src in addition to g-protein 
receptors [49]. Finally, p38 is activated by several 
cytokines and is an important regulator of hematopoiesis 
through transcription factor activation [50].
 We also did a similar comparison based on the 
PCR analysis of the qPCR cohort; we then compared the 
phosphoprotein profiles for the 10 patients with the highest 
and the 7 patients with the lowest CXXC5 expression. 
We detected increased phosphorylation also of several 
additional intracellular mediators for CXXC5LOW patients 
(p<0.05 for all). Firstly, STAT1 (Y701) phosphorylation 
was increased; this mediator has an overlapping repertoire 
with STAT3 [49] and is a downstream target of Akt 
[46]. Secondly, STAT6 (Y694) phosphorylation was 
increased. STAT6 is activated by IL4/IL13 that reduce the 
constitutive release of several cytokines by primary human 
AML cells [51, 52]. STAT6 is also a regulator of normal 
Figure 6: The effect of pharmacological inhibition on 
CXXC5/RINF mRNA expression levels. Primary human 
AML cells were cultured with GDC0941 for 5 hours before 
CXXC5/RINF mRNA levels were compared for drug-free 
control cultures and drug-containing cultures (Wilcoxon’s test 
for paired samples, p=0.0479).
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hematopoiesis [53] and several genetic loci encoding 
chemokines and adhesion molecules contain STAT6-
binding motifs [54]. Finally, ERK1/2 phosphorylation 
(T202/Y204) was altered and CREB is one of its 
downstream targets [55].
We finally compared the alterations in 
phosphorylation status when cells were incubated with 
7 exogenous cytokines. The overall phosphoresponse 
differed between CXXC5HIGH and CXXC5LOW patients 
from the PCR cohort, the most striking difference being 
that only CXXC5LOW patients showed an increased 
phosphorylation of STAT3(S727), rpS6(S235/6) and 
STAT5(Y694) in response to GM-CSF (Figure 5B). Only 
minor differences were detected for other mediators 
in response to IL3, Flt3-L, SCF, CXCL12 and IFNγ. 
Similar GM-CSF-induced alterations were detected when 
comparing the 21 CXXC5HIGH and the 21 CXXC5LOW 
patients in the microarray patient cohort (Figure 5C). 
Inhibition of CXXC5 expression by 
pharmacological intervention
We investigated pharmacological effects on CXXC5 
expression for primary human AML cells after 5 hours of 
in vitro exposure. CXXC5 expression showed a difference 
of only borderline significance for the pan-PI3K inhibitor 
GDC0941 (Figure 6, p=0.0479). We observed divergent 
effects without statistically significant alterations for the 
PKC agonist PEP005, lenalidomide, the proteasomal 
inhibitor bortezomib, the mTOR inhibitor rapamycin, 
the HSP90 inhibitor 17-DMAG, the HSP70 inhibitor 
VER-155008 and the protein kinase inhibitors PD98059, 
SB202190 and SP600125 (data not shown). These data 
suggest that CXXC5 expression integrates signaling 
through various pathways, and the contribution of each 
pathway differs between patients. 
Effects of CXXC5 knockdown on gene expression 
in human AML cells
CXXC5 was knocked down by lentiviral vectors 
in three different AML cell lines; one vector with 
pyromycine selection was used for MV4-11 (759 genes 
upregulated and 744 genes downregulated at least 1.5 
fold) and K562 cells (870 genes upregulated and 758 
genes downregulated at least 1.5 fold) and another vector 
based on GFP sorting was used for knockdown in K562 
(356 genes upregulated and 457genes downregulated at 
least 1.5 fold) and UT7 cells (1291 genes upregulated 
and 827 genes downregulated at least 1.5 fold). CXX5 
knockdown was documented both at the mRNA and 
protein level for all experiments. These genes were 
compared with the 50 genes showing highest mRNA 
expression in the CXXC5HIGH and CXXC5LOW patient 
subset (see Supplementary Tables 1 and 2). 
Global gene expression profiles were compared 
for cells transfected with knock-down vectors and emty 
control vectors. Four genes were identified according 
to the following criteria: (i) being among the 50 genes 
with highest expression in CXXC5HIGH/LOW patients 
(Supplementary Tables 5 and 6); and showing either (iia) 
>2-fold alteration after CXXC5 knockdown for one cell 
line or (iib) >1.5-fold alteration for two different cell lines. 
All four genes showed high levels for CXXC5HIGH patients 
increased levels after CXXC5 knockdown, and their 
relevance for carcinogenesis/leukemogenesis is described 
in detail in Suppl. Table 7 and summarized below. 
Increased levels of the potential tumor suppressor 
gene TSC22D1. This gene (TSC22 domain family, member 
1) shows increased levels after CXXC5 knockdown and 
encodes a transcriptional regulator [56] that is a potential 
tumor suppressor in human AML [57]; it can also 
contribute to induction of apoptosis in human gastric and 
breast cancer cells and increase cancer cell sensitivity to 
anticancer drugs [56] and radiation [58]. 
Increased levels of the cell cycle regulator SEPP1. 
The encoded mediator (Selenoprotein P.plasma.1) is a 
secreted glycoprotein containing extracellular selenium 
[59]. Selenium and its metabolites are involved in 
regulation of apoptosis and proliferation/cell cycle 
progression [60].
Increased expression of the receptor for the Stem 
cell factor (KIT) and for Angiopoietin 1 (ANGPT1). 
KIT shows increased levels and encodes CD117 that 
is expressed by primary human AML cells for most 
patients but its expression has no prognostic impact for 
AML patients receiving intensive chemotherapy [61]. 
ANGPT1 (Angiopoietin 1) is a Tie2 agonist that shows 
increased expression in CXXC5HIGH cells. Angiopoietin 
1 is a regulator of angiogenesis without any prognostic 
impact by itself in human AML, whereas extracellular 
levels (serum, bone marrow plasma) of the potential 
Tie2 antagonist Angiopoietin 2 has an adverse prognostic 
impact in human AML [62-64]. Finally, ANGP1 is also 
a member of the leukemic stem cell gene expression 
signature that has been associated with adverse prognosis 
in human AML [33]. The extracellular release of 
Angiopoietin 1 showed a wide variation during in vitro 
culture (median 37 pg/ml, range <0.5 pg/ml to 2135 
pg/ml) and a correlation was seen between the level of 
Angiopoietin 1 mRNA expression and the level of protein 
release (p=0.001).
The expression of the transcriptional regulators 
showing correlated mRNA expression with CXXC5 was 
not altered by the knockdown (see above). 
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CXXC5 expression increases during progression 
of chronic myeloid leukemia to blast phase 
We previously described that CXXC5 is 
expressed in AML as well as acute lymphoblastic 
leukemia cells [4]. In our present study we compared 
CXXC5 expression in chronic myeloid leukemia cells; 
we then used previously published global gene expression 
data [65]. CXXC5 expression was low for CML bone 
marrow cells in chronic phase, the levels increased during 
accelerated phase and were highest for patients in blast 
phase (Fig. 7). Thus, high/increasing CXXC5 expression 
is associated with more aggressive disease not only in 
AML but also in CML. 
DISCUSSION 
The CXXC5 gene seems important during both 
normal and leukemic hematopoiesis [2]. High expression 
in the leukemic cells is an independent adverse prognostic 
factor in AML [5] and possibly associated with adverse 
prognosis also in other myeloproliferative diseases, e.g. 
CML [66].
CXXC5 encodes a transcriptional regulator [3]. Our 
present studies suggest that this protein is a part of a larger 
transcription-regulatory network that differs between 
CXXC5LOW and CXXC5HIGH patients and includes several 
stem cell associated transcription factors as well as a 
heptade of transcription factors associated with an adverse 
prognosis in human AML [34]. Our bioinformatical 
analyses demonstrated that CXXC5 expression showed 
a strong association both to (i) the overall expression 
profiles of the transcription factor heptade associated 
with adverse prognosis (Figure 3); and (ii) the overall 
signature of 35 stem cell-associated genes used to identify 
AML patients with high-risk disease (Figure 4). CXXC5 
expression levels also showed significant correlation with 
several genes included both in the transcription factor 
heptade and in the stem cell gene expression profile. 
Thus, the association between high CXXC5 expression 
and adverse prognosis is seen in a biological context of 
a specific transcription-regulatory network and an AML 
stem cell-associated expression signature. The hypothesis 
that CXXC5 is a part of a larger transcription-regulatory 
network is also supported by our similarity gene 
expression analysis and the corresponding protein function 
analysis (Figure 1).
Our comparison of gene expression profiles in 
contrasting CXXC5HIGH and CXXC5LOW patients identified 
571 genes with different expression (Supplementary 
Figure 2). The analysis of corresponding protein functions 
suggests that these two contrasting groups show major 
differences with regard to communication between cells, 
i.e. expression of various cell surface molecules (including 
cytokine receptors) and release of soluble mediators 
(Figure 1, Table 2). However, there was also an overlap 
between protein functions identified through the CXXC5 
similarity expression analysis and the GSEA analysis of 
contrasting patient subsets (Figure 1, left part). 
We compared the constitutive cytokine release for 
primary human AML cells with high and low CXXC5 
expression but could not detect any difference when 
comparing single cytokine levels (Supplementary Table 3) 
but only with regard to cytokine clustering (Supplementary 
Figure 3). The effect of lenalidomide on cytokine release 
Figure 7; CXXC5/RINF is increased during the progression of chronic myeloid leukemia from chronic phase to blast 
crisis. The microarray data have been performed by Radich JP et al. [65]. The CXXC5/RINF gene expression data were extracted from 
a gene list (supporting table 4 or 10423Table4.xls) available online at the PNAS website (http://www.pnas.org/content/103/8/2794/suppl/
DC1). CP: chronic phase (n=42), AP: accelerated phase by blast count criteria (n=9) or by the occurrence of additional clonal cytogenetic 
changes (n=8), BC: blast crisis (n=28).
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also differed between the subsets, and these effects could 
not be explained by a nonspecific effect secondary to 
altered viability because a similar effect on all cytokines 
would then be expected. However, the wide variation 
in constitutive release is definitely the most important 
difference between AML patients and this variation is 
similar for CXXC5HIGH and CXXC5LOW patients; the 
differences in cytokine clustering and lenalidomide effects 
should only be regarded as minor differences. 
We compared the intracellular phosphoprotein 
status for CXXC5HIGH and CXXC5LOW AML cells. Our 
high-throughput technique requires an incubation step for 
antibody binding [14]; we then used a medium suitable 
for immature hematopoietic cells and containing insulin 
and transferrin but no hematopoietic growth factors [43, 
44] and we refer to this as basal phosphorylation status. In 
addition we compared growth factor-induced alterations 
of protein phosphorylation. The low-risk CXXC5LOW 
patients showed increased basal phosphorylation of 
several mediators. Additional differences were induced 
by exogenous growth factors, especially GM-CSF/
IL3-induced increase of STAT5 phosphorylation. Thus, 
variation in CXXC5 expression is associated with 
differences in intracellular signaling targeting downstream 
transcription factors. 
Our studies suggest that signaling though PI3K-
Akt is important for CXXC5 expression, and several 
of the mediators showing different phosphorylation for 
CXXC5HIGH and CXXC5LOW patients are downstream 
targets to PI3K-Akt-mTOR (see above). Some of the 
genes identified in the CXXC5 similarity profiling are 
also important for this pathway (Supplementary Table 
2A). All these observations suggest that the pathway is 
important for regulation of CXXC5 expression. Finally, 
pharmacological inhibition of other intracellular pathways 
had divergent effects, these observations then being 
consistent with the hypothesis that regulation of CXXC5 
mRNA expression differs between patients and depends 
on several/various intracellular signaling pathways.
Previous studies suggest that high constitutive 
signaling through the PI3K-Akt-mTOR pathway [67, 
68] and activation of its downstream target STAT3 
[69] is associated with adverse prognosis in human 
AML. However, a recent study suggested that AML 
patients are heterogeneous and signaling through this 
pathway can cause growth inhibition as well as growth 
enhancement in primary AML cells [70]. STAT3 shows 
an extensive and cell type-dependent variation in its 
preference to potential DNA binding sites [71, 72], and 
a similar variation between biologically heterogeneous 
AML patients may explain the different biological effects 
of PI3K-Akt-mTOR-STAT3 signaling between AML 
patients [73]. Furthermore, the possible prognostic impact 
of STAT3 activation in human AML is also controversial. 
Benekli et al. [69] described an association between 
high constitutive STAT3 activation (i.e. high Y705 
phosphorylation) and adverse prognosis, whereas a recent 
study described improved survival for patients showing 
high STAT3 Y705 and S727 phosphorylation in their AML 
cells in response to cytokine stimulation [74]. This last 
observation is consistent with our present observation of 
an association between high STAT3 phosphorylation for 
lowrisk CXXC5LOW patients. One possible hypothesis 
for these apparently conflicting observations could be 
that the prognostic impact of STAT3 in human AML is 
not (only) mediated by its phosphorylated form, but by 
the unphosphorylated form and its interaction with NFκB 
signaling [72]. This hypothesis is also consistent with the 
previously described associations between phosphorylated 
forms of STAT3 and antiproliferative/proapoptotic effects 
in human cancer cells [75] and stem cells [76], during 
murine carcinogenesis [77] and in STAT3 knock-down 
models [78]. 
STAT5 phosphorylation/activation can also 
mediate proapoptotic effects through activation of 
growth inhibitory and proapoptotic genes depending 
on its biological context [79], and this may also explain 
the association between the CXXC5LOW phenotype and 
increased STAT5 phosphorylation after GM-CSF/IL3 
exposure. Finally, increased CREB phosphorylation was 
observed for CXXC5LOW patients, but this may be less 
important because animal models suggest that CREB only 
contributes to the AML phenotype but is not sufficient 
for leukemic transformation [48]. Thus, the increased 
phosphorylation of these intracellular mediators for 
lowrisk CXXC5LOW patients may contribute to the good 
prognosis for these patients due to the biological context, 
i.e. crosstalk between pathways or interactions with other 
transcriptional regulators [80].
Based on the knockdown experiments and analysis 
of global gene expression profiles (Supplementary Tables 
5 and 6) we identified four genes that both were altered 
by CXXC5 knockdown and whose expression showed 
a strong correlation with CXXC5 expression in primary 
AML cells. These genes were increased by CXXC5 
knockdown; this can be explained by an inhibitory effect 
of CXXC5/RINF on their expression and stimulatory 
effect(s) by other transcriptional regulators that show 
strong correlation with CXXC5 expression (see above). 
Those genes showing high expression in CXXC5HIGH 
primary human AML cells and being significantly altered 
(i.e. increased ) after CXXC5 knockdown included 
one potential tumor suppressor (TSC22), the cytokine 
Angiopoietin 1, a selenium transport protein and the 
hematopoietic growth factor receptor KIT. The three 
first may be important for regulation of apoptosis or cell 
cycle progression in human malignant cells, whereas 
the KIT receptor mediates growth-enhancing effects in 
human AML cells although it does not have any impact 
on chemosensitivity/prognosis (Supplementary Table 7). 
Thus, these knockdown experiments further support a role 
of CXXC5/RINF in AML chemosensitivity. 
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To summarize, CXXC5 expression shows a wide 
variation in primary human AML cells and high levels 
are associated with an adverse prognosis. Our present 
results suggest that CXXC5 integrates several intracellular 
signaling events and thereby have effects of several steps 
in regulation of leukemogenesis or chemosensitivity in 
human AML. 
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